We should be clear that there are many things that Lumigenix has done well, especially compared to companies occupying the lower end of the direct-to-consumer genetics market – this is absolutely not a cowboy operation. We particularly liked Lumigenix’s collaboration with the Mayo Clinic, which is a sensible way of obtaining reliable disease information without needing to invest heavily in in-house curation.
However, Lumigenix can’t help but suffer from comparisons to 23andMe, a company that beat it to market by over three years and now thoroughly dominates the direct-to-consumer genomics industry. The overall experience feels more-or-less likea less satisfying version of 23andMe: the common disease, trait and ancestry prediction systems are all broadly similar, but with a less sophisticated interface, and many of the more interesting components of the 23andMe service (such as carrier testing, pharmacogenomic markers, genome sharing, family inheritance patterns, Relative Finder) feel quite conspicuous in their absence. Then there’s the price: the Lumigenix test currently retails for USD$479 while 23andMe is USD$399 (without subscription).
- More Here
However, Lumigenix can’t help but suffer from comparisons to 23andMe, a company that beat it to market by over three years and now thoroughly dominates the direct-to-consumer genomics industry. The overall experience feels more-or-less likea less satisfying version of 23andMe: the common disease, trait and ancestry prediction systems are all broadly similar, but with a less sophisticated interface, and many of the more interesting components of the 23andMe service (such as carrier testing, pharmacogenomic markers, genome sharing, family inheritance patterns, Relative Finder) feel quite conspicuous in their absence. Then there’s the price: the Lumigenix test currently retails for USD$479 while 23andMe is USD$399 (without subscription).
- More Here
No comments:
Post a Comment